Simplified Chinese
scroll down
04
2025-09
Remember history, honor our heroes; strengthen our national defense, and rejuvenate the Chinese nation. On the morning of September 3, 2025, a grand commemorative rally marking the 80th anniversary of the victory of the Chinese People’s War of Resistance Against Japanese Aggression and the World Anti-Fascist War was solemnly held at Tiananmen Square in Beijing. Minhai Biotechnology promptly issued a notice, organizing all employees to gather in the multi-purpose conference hall to watch the live broadcast of the military parade, jointly witnessing this solemn and inspiring historical moment. The event aimed to guide employees in deeply commemorating the outstanding achievements of revolutionary martyrs, truly appreciating the nation’s growing comprehensive strength and the remarkable accomplishments of its modernized national defense, thereby further igniting patriotic enthusiasm and rallying collective momentum for progress. During the broadcast, all employees…
29
2025-08
Recently, Shenzhen Kangtai Biological Products Co., Ltd. has launched a research and development project for a globally innovative vaccine—Pneumonia‑causing Klebsiella pneumoniae vaccine. Kangtai Biologics will actively advance preclinical studies, clinical trials, and subsequent industrialization efforts for this vaccine. Klebsiella pneumoniae is currently one of the most drug‑resistant and virulent bacteria in clinical practice, often referred to as the “king of superbugs.” In particular, carbapenem‑resistant Klebsiella pneumoniae (CRKP) exhibits resistance to virtually all first‑ and second‑line antibiotics. According to the 2024 National Hospital‑Acquired Infection Prevalence Survey Report (12th edition), Klebsiella pneumoniae remains the pathogen with the highest detection rate.
28
2025-08
Recently, Shenzhen Kangtai Biological Products Co., Ltd. has launched a research and development project for a globally innovative vaccine—Pneumonia‑causing Klebsiella pneumoniae vaccine. Kangtai Biologics will actively advance preclinical studies, clinical trials, and subsequent industrialization efforts for this vaccine. Klebsiella pneumoniae is currently one of the most drug‑resistant and virulent bacteria in clinical practice, often referred to as the “king of superbugs.” In particular, carbapenem‑resistant Klebsiella pneumoniae (CRKP) exhibits resistance to virtually all first‑ and second‑line antibiotics. According to the 2024 National Hospital‑Acquired Infection Prevalence Survey Report (12th edition), Klebsiella pneumoniae remains the pathogen with the highest detection rate.
26
2025-08
Kangtai Minhai’s partner has received a drug registration certificate issued by Indonesia’s National Agency of Drug and Food Control (BPOM), approving the marketing of a “dual‑carrier” 13‑valent pneumococcal polysaccharide conjugate vaccine that is locally filled and packaged in Indonesia. This marks the first product of Kangtai Minhai to be approved for market launch following technology transfer overseas and local filling and packaging, representing a milestone in the company’s long‑standing internationalization strategy of integrating “bringing in” with “going out.” The 13‑valent pneumococcal conjugate vaccine covers 13 common serotypes of Streptococcus pneumoniae that are highly pathogenic, thereby protecting children from pneumococcal‑related diseases.
25
2025-08
On July 28, 2025, the first Biopharmaceutical Base Safety Production Competition concluded successfully. Relying on solid safety knowledge, expert operational skills, and outstanding team collaboration, Minhai Biotechnology won the prestigious first-place award in the highly competitive confined-space operations event. This achievement fully demonstrates Minhai Biotechnology’s exceptional management standards in the field of workplace safety—particularly in high-risk operations—and its employees’ robust, real-world capabilities. The inaugural Safety Production Competition was meticulously organized by the Daxing District Biopharmaceutical Base Management Committee, featuring four key disciplines: fire emergency response, hazard identification, confined-space operations, and electrical safety, with the aim of comprehensively enhancing safety across the entire industrial park.
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%